Doral, FL – February 06, 2020 – Earth Science Tech Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces it has canceled 18,000,000 common shares along with 5,200,000 Series A Preferred shares through a confidential settlement with Majorca LTD, the majority shareholder. The Company now has zero preferred shares outstanding and 36,384,394 common shares outstanding which is down from 53,902,354.
ETST’s President, Director and Chairman Nickolas S. Tabraue stated, “We are extremely pleased to have reached a settlement with Majorca, LTD and the value it adds for our shareholders is immediately recognized and meaningful.”
About Earth Science Tech Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. Based on its studies through the University of Central Oklahoma, DV Biologics, and key organizations, ETST formulates, markets and distributes the CBD formula used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has two wholly owned subsidiaries and favored entity focused on developing its role as a world leader in the CBD space, expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly owned subsidiary of Earth Science Tech committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
Cannabis Therapeutics Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science Tech Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol.
Earth Science Foundation Inc.
Earth Science Foundation (“ESF”) is a favored entity of Earth Science Tech Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need.
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director, & Chairman
(305) 615-2118 Office
Source: Earth Science Tech, Inc.
DORAL, Florida (January 23, 2019) Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces its partnership with Iq2 Labs to formulate a CBD Mental Clarity and Focus shot, compared to leading energy shot brands, High Grade Full Spectrum Iq2 Cannabinoids.
The Company has partnered with Iq2 Labs due to their effective high quality medically supported ingredients used in their IQ2 products sold in vegetable capsules. IQ2 alone works great and fast as well as the Company’s High Grade Full Spectrum Cannabinoids, combining both would synergistically enhance one another and in a liquid shot form would increase the metabolic effect, therefor having the benefits felt rapidly. Based from our High Grade Full Spectrum Iq2 Cannabinoids trials, consumers may experience; mental clarity, calmness, stress relief, clean energy, improved memory retention, improved blood and oxygen circulation, and an uplifting sensation.
High Grade Full Spectrum Iq2 Cannabinoids is currently going through the package designing process and once finalized, the ready made formula will be bottled, launched, and plugged into ETST’s growing sales channels.
Nickolas S. Tabraue, chairman of ETST, adds, “This partnership offers us to tap into the emerging CBD beverage industry with a current effective formula while our science team continues to develop a CBD beverage utilizing our University of Central Oklahoma provisional patent, announced last year October. High Grade Full Spectrum Iq2 Cannabinoids will a great add-on to our line offering individuals an immediate clean mental boost.”
About Iq2Labs
Iq2 Labs offers medically supported nootropic supplements to consumers looking to keep their brain sharp and vibrant.
To learn more, please visit: www.iq2labs.com
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office
Source: Earth Science Tech, Inc.
DORAL, Florida (December 20, 2018) – Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces it is taking advantage of the new Farm Bill, which is set to legalize hemp cultivation and hemp-derived CBD and other products in the United States, by signing David Barbash as its chief sales officer beginning in 2019. Mr. Barbash is a results-driven sales and marketing professional with more than 20 years of new business development to his credit and is a proven negotiator, manager and motivator.
As has been widely publicized, the 2018 Farm Bill, being signed soon, removes hemp (including hemp-derived cannabinoids containing less than 0.3% THC) from the Controlled Substances Act and transfers oversight of these products from the Drug Enforcement Agency to the U.S. Department of Agriculture. The new classification will allow domestic banks to now accept and process transactions related to hemp-derived cannabinoid-based products and opens doors to commercialize these products in the mass market. New Frontier cannabis market data projects the American CBD market will reach $2.3 billion in revenues by 2022.
To further take advantage of and capitalize on this amazing new opportunity, the Company has transitioned Jill Buzan, ETST’s current chief sales officer, to direct the Company’s sales in Florida while Mr. Barbash steps in as the new chief sales officer beginning in 2019. Mr. Barbash will begin distributing ETST’s cannabinoid products through his nationwide small, medium and large chain retail accounts.
Mr. Barbash brings to the Company more than 25 years of natural products industry experience in both the U.S. and U.K. markets, having previously worked with niche forward-thinking companies like Health From The Sun/Arkopharma, Pure Essence Labs, and Harmonic Innerprizes. He brings extensive international experience and a high level of enthusiasm to his new role at ETST.
“It’s an incredibly exciting time at ETST, and I am very thankful to be heading up the team that is going to lead the way in the cannabinoid sector when it comes to product efficacy, purity and clinically backed effectiveness,” Mr. Barbash states. “In 2019, through increased distribution, an expanded sales force, further emphasis on education and projected record sales, we hope to provide a banner year for our customers, future customers and, ultimately, the consumer.”
Nickolas S. Tabraue, president, director and chairman of ETST, states, “We are thrilled to add David to our team, and we look forward to an exciting year as he steps in as ETST’s new chief sales officer. His expertise and enthusiasm will be tremendous assets as we ride the wave opportunity afforded by the legalization of hemp cultivation and hemp-derived CBD in the United States.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office
Source: Earth Science Tech, Inc.
Launch of new medical device to fight STIs slated for early 2019
DORAL, Florida (December 18, 2018) Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces the production of the first commercial production run of Hygee™, its new, original medical device to fight sexually transmitted infections (STIs). The official launch is scheduled for early 2019.
After numerous partnerships, tests, distribution agreements and prepping, ETST has officially ordered a first production run of Hygee™. Initial marketing will target North America, South America, Asia and Africa, and the Company will package Hygee™ in English, French, Portuguese, Spanish, Vietnamese and Arabic to reach an wide audience of consumers. These languages are mother tongues for 1.5 billion people, with many other ethnic groups using English as a second language. By offering Hygee™ in different languages, ETST can reach the majority of individuals globally, as well as those in the Company’s current agreed distribution network, shared in November.
The Hygee™ self-sampling kit includes a discreet, wearable medical device that enables a woman to anonymously test for STIs such as chlamydia. Testing for this disease is particularly important for pregnant women, who must be screened for chlamydia infections to minimize the risk of transmission of the infection to their babies during childbirth. In any given year, approximately 8 million women give birth in the United States, Canada, Brazil, Mexico, Morocco, Djibouti, and Vietnam where Hygee™ will first be offered.
While this niche represents a considerable market for the Hygee™ medical device, opportunity exists well beyond pregnant women. The World Health Organization recommends that all sexually active women aged 15 to 25 get tested yearly for chlamydia, representing a market of about 500 million women worldwide .
Dr. Michel Aube, ETST’s CEO and chief science officer, states, “No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygee™. Through intentional design, Hygee™ is a ‘mistake proof’ medical device with extremely simple instructions that allow any woman, regardless of age or education the assurance of correctly using the kit on the first try. With roughly 130 million new chlamydia cases diagnosed yearly, according to the WHO, Hygee™ is dedicated to this area of women’s health.”
ETST’s projections for Hygee™ anticipate strong sales growth in years two and three after product launch. As soon as year one, sales of Hygee™ and the associated in vitro molecular diagnoses should reach between $1.5 million and $2.5 million USD. Second year sales should reach $1 million monthly and up to $20 million yearly as early as the third year. These numbers are supported by the fact that chlamydia is a global issue; that the company’s network of distributors is worldwide; and that the thin yet stable structure of the device ensures that it can be easily dispersed on all continents.
“We believe that ETST has developed the best tool on the market to fight STIs, which will provide an exceptional service to women who use Hygee™,” states Nickolas S. Tabraue, the company’s president, director, and chairman. “The production of the first batch of Hygee™ is very exciting. Our team believed in the success of Hygee™ from the first day we acquired it. Now, we will do everything possible to spread this fabulous medical device everywhere on the planet to protect women and their future babies from the terrible, adverse effects of chlamydia and other STIs.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office
Source: Earth Science Tech, Inc.
DORAL, Florida (December 13, 2018) Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces successful in vitro analyses of gynecological samples collected using its new Hygee™ medical device.
Hygee™ is a discreet, wearable medical device that enables a woman to anonymously test for sexually transmitted infections (STIs). As previously announced, samples collected by the Hygee™ device are tested by Procréa and Dermagate. In pre-launch testing at the labs, molecular diagnostic assays successfully identified the presence of Chlamydia in test subjects, confirming earlier testing results.
ETST’s President, Director and Chairman Nickolas S. Tabraue states, “We are pleased to announce positive testing in the pre-launch phase of Hygee™, and would like to thank our carefully selected partners, Procréa and Dermagate, for a job well done. They are the guarantee of our success.”
ETST is on track to launch Hygee™ in early 2019. The Company plans to market the product through its established distribution channels, mentioned in November, thanks Dermagate’s ISO 13485:2013 certification.
“Hygee™ is an incredible innovation, and we have partners from many countries waiting to market the device,” stated ETST CEO and Chief Scientific Officer Dr. Michel Aube. “This is only the beginning of realizing the potential of this unique device, and we look forward to updating our shareholders on our progress.”
In its first iteration, Hygee™ will be marketed as an at-home test for chlamydia; however, R&D efforts currently underway indicate that Hygee™ will soon be certified for gonorrhea testing as well.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office
Source: Earth Science Tech, Inc.
DORAL, Florida (December 7, 2018) Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that as the Company is now an “OTC reporting issuer” in the Province of Québec, Canada, its board of directors is considering a dual listing of its common shares on the Canadian Securities Exchange (CSE).
Earth Science intends to file an application with the CSE in early 2019. Listing could happen as early as in the third quarter of the Company’s current fiscal year and would require certain regulatory approvals that would allow Earth Science to market and sell its common shares to Canadian investors.
“The Canadian Securities Exchange has seen significant increases in trading, particularly in the cannabis and CBD space. We feel that by listing on the two exchanges we will attract more investors in both the U.S. and Canada, creating further liquidity and increasing our ability to raise capital in a different market. With our R&D operations conducted in Canada and our CEO residing in Canada, considering a listing on the CSE makes the most sense,” states Earth Science president, director and Chairman Nickolas S. Tabraue.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office
Source: Earth Science Tech, Inc.
DORAL, Florida (December 07, 2018) Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that the new genuine CBD/Propovit throat spray formula developed through a strategic partnership with Bionatus is nearly market-ready.
As previously announced, ETST collaborated with Bionatus to improve the Propovit throat spray. The result is a new strawberry-flavored formulation enriched with ETST full-spectrum cannabinoids derived from industrial hemp.
Dr. Michel Aube, ETST’s CEO and chief science officer states, “We are very excited to see this project in the final stage. We have developed a product that we believe will have properties not found in any other product on the market, and we thank our team and our partner Bionatus for their diligence and innovation on this formulation. ”
The main active ingredient in Propovit is propolis, a compound derived from the Brazilian green bee and packed with strong antioxidants as well as potent anti-bacterial, anti-viral, anti-fungal and anti-inflammatory properties. The new formulation combines the effect of Propovit and ETST’s cannabinoids to help diminish the symptoms of throat infections via fine drops that spread the hemp oil widely onto the oromucosal part of the mouth.
ETST also plans to conduct clinical trials on the genuine CBD/Propovit formula to measure the combined effects of these two powerful components on throat infections.
“The focus and patience of this project are rewarding. The determination of our team to continuously propel ETST is what fuels our success. We are united in our goal to deliver to people the best products to help them to have a better and healthier life,” states ETST president, director and Chairman Nickolas S. Tabraue.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office
DRTV campaign includes powerful customer review of ETST’s CBD products
DORAL, Florida, Nov. 14, 2018 – Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that it has commenced filming of its direct response television (DRTV) media campaign with mega-entrepreneur Kevin Harrington’s award-winning As Seen On TV production company. The film will include an interview with a customer whose life was positively changed by ETST’s High Grade Full Spectrum Cannabinoids.
As announced in September, ETST signed an agreement for an As Seen On TV campaign that will include a 60-second DRTV commercial spot to be aired 300 times within 10 selected regions and selected networks; a 15-second promotional video to be used for digital and social media purposes; a featured placement on the website for 12 months; complete licensing rights to the commercial spot and promotional video; and permission to use the world-famous As Seen On TV logo on ETST’s products.
Production of the campaign begins in Ft. Lauderdale, Florida, where Rhoda Friedman shares how ETST’s CBD products have provided relief from pain she has endured for 31 years.
“I’ve been on ETST’s CBD since April 2017. I am 73 years old and I have been in excruciating pain from approximately 1987. Until I started CBD, I was not able to walk steps or stand for more than five minutes without severe pain in my lower lumbar, which I had surgery on eight years ago – and the pain just increased. I was on 29 pills a day and I am happy to say that five days after I began CBD and ever since I have only been on a blood thinner. I have been able to walk, go up and down the steps, dance, and move about in ways I never thought I would ever be able to do again. I have trichotillomania, which is pulling out of the hair, but I have not been affected by it since I’ve been on the CBD. I had a fatty enlarged liver from hepatitis C … three months after I started taking CBD my liver was normal size with no fat – it returned to normal. I also suffered since 1990 with post-traumatic stress disorder where my hands were shaking to the point I could barely feed myself. The shaking totally stopped within the first day of the CBD. I also suffered from obsessive compulsive disorder to the point where it disrupted a lot of my activities. I no longer suffer from that. I had anxiety attacks … I no longer suffer from that. In short, my life is back to what it was when I was in my 40s and suffered from none of it.”
The film will air nationwide in the first quarter of 2019, and will also be shared via social media for optimal brand awareness. ETST owns the rights to the material, as well as how it will be disseminated and utilized in retail locations.
ETST president, director and Chairman Nickolas S. Tabraue stated, “I am excited that we have started production and that we have Rhoda Friedman to share her amazing story with the world. Rhoda is an amazing woman. Everyone with whom she shares her life-changing experience with our products can see and feel her passion. Once production is complete, I will share updates and share the material that is being put together by Kevin Harrington’s amazing team.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTich i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com 212.418.1217 Office
Editor@NetworkNewsWire.com
Source: Earth Science Tech, Inc.
DORAL, Florida (October 18, 2018) Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today shares it has started formulating a full spectrum CBD beverage utilizing its University of Central Oklahoma Provisional Patent to improve immune system functions.
To stay innovative in the CBD industrial the Company is always looking for new ways to deliver its effective cannabinoids to the public and continue positively change individuals lives. While the Company continues to perfect its CBD nutraceutical provisional patent products, they have also started to formulate a beverage utilizing its University of Central Oklahoma provisional patent with the help of Dr. Aube, his advisory team and the Company’s current manufacture near its headquarters.
The new High Grade Full Spectrum Cannabinoids beverage (the CBD beverage) will be focused on immunity due to its positive results with the Company’s collaboration with the University of Central Oklahoma during 2015. The company is currently working on the CBD beverage formula and looking into different bottling options with its current manufacture. The CBD beverage will allow the Company to tap into the predicted $11.7 billion this year and grow $25 billion in seven year cannabis beverage market.
Michel Aube, ETST’s CEO & CSO comments,”The CBD beverage is a most in the époque of legalization of recreative marijuana. Not only does CBD have positive effects on immune cells, it has strong antioxidant and anti-psychotic properties. Indeed, it is now well recognized that CBD is an anti psychotic molecule and that CBD has opposite effect to Δ-9-tétrahydrocannabinol (THC). This is why health professions are concerned by the fact that most marijuana plants have very low concentration of CBD and huge amount of THC molecule. At Earth Science Tech we focused on full spectrum cannabinoids derived from industrial hemp that contains extremely low to no THC since THC is psychoactive causing dependency and mental illness in young individuals. This means that all our products are beneficial for recreational marijuana consumer because it helps them to balance their intake of psychoactive and anti-psychotic cannabinoids. Our cannabinoid products help to counter the side effects of THC in addition of having itself other interesting biological activities like anti-inflammatory and antioxidant properties.”
ETST president, director, and Chairman Nickolas S. Tabraue stated, “This a great opportunity for us while the cannabis beverage market is in the emerging stage and forecast to grow exponentially. I look forward on sharing updates as we progress with our new CBD beverage product”.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors::
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTich i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Source: Earth Science Tech, Inc.
DORAL, Florida (October 11, 2018)- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that it has entered talks for a potential exclusive business/supply agreement with an organic CBD grower and processor.
ETST is interested in utilizing the grower and processor’s outdoor organic industrial hemp plants, extraction, mixing, bottling and packaging capabilities on an exclusive basis. ETST believes an exclusive development, licensing, and supply agreement with the grower and processor would enable a consistent, marketable industrial hemp source, potentially increasing revenues for both ETST and grower.
ETST president, director, and Chairman Nickolas S. Tabraue stated, “This is a huge opportunity for Earth Science Tech and one that has the potential to dramatically change our dynamics. If completed, this exclusive agreement would enable us to fulfill our many industrial hemp raw bulk inquires, further expand our revenues, and lower our cost of finished goods, all while offering optimal full Spectrum Cannabinoids quality as well as unique cannabinoid products through the grower and processor’s innovative technologies. I plan on sharing more updates as we progress to a final agreement.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors::
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTich i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Source: Earth Science Tech, Inc.
DORAL, Florida (October 3, 2018) – Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today provides an update on the progression of its cannabidiol (“CBD”) patents and reacts to the U.S. Drug Enforcement Agency’s (“DEA”) recent decision to remove certain CBD products from its Schedule 1 list of controlled substances.
As previously announced, ETST will soon launch its two CBD-based nutraceutical formulas – a neuron protector and a breast protector – under the provisory patent. In tandem, the Company is developing a new brand for these two formula patents.
ETST further announces that the Quebec Agrifood Innovation Center (“QAIC”) is finishing the standardization of the formulas. By the end of October, TransBiotech will conduct in vitro testing for the formulas’ biological activities, comparing the level of protection provide by ETST’s hemp oil alone versus its hemp oil with other natural ingredients. These components have been meticulously chosen for their bioactivity.
“The results obtained from TransBiotech will help us understand the mechanism of action of CBD and will open the doors for the research needed to develop revolutionary CDB-based pharmaceutical drugs,” says ETST president and CEO Nickolas Tabraue. “We will provide more details on the progress of these formulas in the near future, as well as an update on the first CBD-based pharmaceutical product we are developing with Bionatus for the treatment of asthma, as announced last year.”
In addition to nutraceutical formulas, ETST’s pipeline also includes CBD-based pharmaceutical formulas. As legalization of cannabis and cannabis-based products continues to spread, ETST expects that its pure hemp oil and new formulas will eventually be sold worldwide. As , ETST will be a licensed distributor and will work closely with pharmacists and researchers to serve the burgeoning cannabis market.
This expectation is emboldened by the DEA’s recent decision to reclassify FDA-approved drugs that contain cannabis-derived CBD and less than 0.1% tetrahydrocannabinol (THC) as schedule V, the lowest restriction classification. The decision follows the FDA’s first approval of a non-synthetic CBD-based drug to treat rare types of epilepsy.
Once the ruling goes into effect, it could open the door for companies like ETST to develop treatments for other illnesses. The new classification will also render clinical studies with CBD easier to plan.
ETST CEO and Chief Science Officer Dr. Michel Aubé is ecstatic about the changes. “In 2018, we have a much deeper understanding of cannabinoids, cannabinoid-receptors, and the endocannabinoid system than we did decades ago when CBD was classified as a schedule 1 drug. We are pleased to see that the DEA has shifted its stance amid conclusive evidence that CBD is not addictive but has both anti-psychotic properties and the opposite effect of THC.”
ETST plans to share further updates on its CBD patent formulas and CBD-based pharmaceuticals as each progress.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors::
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTich i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Source: Earth Science Tech, Inc.
DORAL, Florida (September 27, 2018) Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, has received updated coverage from SeeThruEquity, which recognizes the Company’s sales growth, recent activity, and market potential. SeeThruEquity also set a price target of $3.60 on shares of ETST.
“We are excited to be covered by a well-respected Wall Street equity firm and are pleased it has taken notice of our recent financial results, recent accomplishments, and positive outlook. This coverage by SeeThruEquity validates the passion and expectations that we at ETST have for the Earth Science brand and our mission to become a leading biotech player,” stated Nickolas S. Tabraue, president, director and chairman of ETST.
View the full SeeThruEquity report here: view report
Report Highlights:
ETST reported sharp growth in its FY1Q19 (ended June 20, 2018), with revenues increasing to $166,891 versus $101,275 in the year-ago period. Revenue growth is attributed to execution in the company’s line of CBD nutraceuticals and supplements, which provide a revenue stream for ETST as it seeks to develop its medical device and pharmaceutical business lines.
Revenues are expected to increase throughout the fiscal year as the company meets demand from expanded retail distribution of its products, supported by pre-sales and a recent replenishment of product which should enable conversion to revenue.
On the direct to consumer front, the company has engaged As Seen On TV to develop a direct response TV and web campaign over the next twelve months, which should provide further demand and an increase in awareness for high-grade CBD oil.
We were pleased to see ETST catch up on its SEC filings with the reporting of its annual financials and FY1Q19 quarterly report. The company announced that its shares were uplisted to be quoted on the OTCQB, which is expected to offer higher liquidity and visibility than OTC.
Our target moves to $3.60 for ETST following recent results and a positive outlook for growth to take shape in coming period driven by expanded CBD sales and the introduction of the company’s medical device MSN-2. We see ETST as a speculative company in the fast-growing CBD space.
SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors::
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTich i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Source: Earth Science Tech, Inc
DRTV campaign to include TV commercial featuring original “Shark Tank” star Kevin Harrington.
DORAL, Florida, Sept. 20, 2018 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields; medical devices; and research and development, announces the commencement of a direct response television (DRTV) media campaign with mega-entrepreneur Kevin Harrington’s award-winning As Seen On TV production company. Considered one of the most successful entrepreneurs in history, Harrington is the renowned inventor of the infomercial and an original “Shark Tank” shark. As part of the agreement with ETST, Harrington will personally appear in an ETST commercial spot to deliver a customized product introduction for the Company.“Kevin Harrington has launched more than 500 products, amassing $5 billion dollars in global sales. A strategic alliance with him and his production outlet positions any company for success,” said ETST President, Director and Chairman Nickolas S. Tabraue. “We are very excited to announce that his analyst team has selected Earth Science Tech, Inc. to collaboratively develop its own As Seen On TV DRTV media campaign.”
As Seen On TV campaign created for ETST will include a 60-second DRTV commercial spot to be aired 300 times within 10 selected regions and selected networks, a 15-second promotional video to be used for digital and social media purposes, a featured placement on the website for 12 months, complete licensing rights to the commercial spot and promotional video, and permission to use the world-famous As Seen On TV logo on ETST’s products.
“It was an honor to get the call from Kevin Harrington’s team that we had been hand-selected to participate in one of their highly coveted DRTV media campaigns,” Tabraue commented. “This is a major opportunity for Earth Science Tech, Inc. to spread its story across the country and continue to positively change many individual’s lives.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTich i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact: www.EarthScienceTech.com Nickolas S. Tabraue President, Director & Chairman 305.615.2118 Office Corporate Communications Contact: NetworkNewsWire (NNW) New York, New York www.NetworkNewsWire.com 212.418.1217 Office Editor@NetworkNewsWire.com
Source: Earth Science Tech, Inc.
DORAL, Florida, Sept. 12, 2018 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields medical devices, and research and development, has been approved by the OTC Markets Group Inc. to up-list to the OTCQB exchange.
As announced in August, the Company initiated the OTCQB up-listing application shortly after the Securities and Exchange Commission (SEC) approved the Company’s Form 10 Registration Statement. ETST is officially an OTCQB fully reporting company as of today, September 12, 2018.
The OTCQB exchange, operated by the OTC Markets Group Inc., facilitates transparent trading for entrepreneurial and development-stage companies that have met a minimum bid price test, are current in their financial reporting, and have undergone an annual verification and management certification process. These standards provide a strong baseline for transparency, as well as the technology and regulation to improve the information and trading experience for investors. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for ETST.
ETST’s President, Director and Chairman Nickolas S. Tabraue comments, “Historically, up-listing to the OTCQB and being fully reporting has resulted in greater liquidity and awareness. We are committed to the higher level of corporate and financial disclosures required as an OTCQB fully reporting company, demonstrating our commitment to our loyal shareholders.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTch i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact: Dave Demarest 305.546.7640 Office Company Contact: www.EarthScienceTech.com Nickolas S. Tabraue President, Director & Chairman 305.615.2118 Office Corporate Communications Contact: NetworkNewsWire (NNW) New York, New York www.NetworkNewsWire.com 212.418.1217 Office Editor@NetworkNewsWire.com
Source: Earth Science Tech, Inc.
DORAL, Florida, July 10, 2018 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, as well as research and development, is pleased to share progress on the company’s CBD IP patent formula development program.
Mentioned in June, the Company currently developing three new CBD formulas and already under the provisory patent.
Two of them are very unique CBD formula products a neuron protector and a breast protector. The company is very bullish on these CBD formulas as the R&D done by the Centre de développement bioalimentaire du Québec (CDBQ) or Quebec Agrifood Innovation Center (QAIC) has been very promising. The team at CDBQ is highly experienced and able to employ the most effective and economical solutions to develop products with the best price-quality ratio on the market. CDBQ is now working on the final formulation that will include an as-yet undetermined natural protective agent to assure the longest possible shelf life of the CBD formula. Several alternatives are now being meticulously tested.
The third CBD formula is a new type of superfood with unique organoleptic properties never seen on the market. Formulated from a mix of hemp oil and other vegetal oil(s), and enriched with a highly potent antioxidant, this product is designed to improve the individuals antioxidant ingestion. The Company has developed this CBD formula with experts that have successfully developed products for some of the largest players in the food industry.
The Company also has two products in development as part of a Joint Venture with Bionatus Laboratório Botânico of Brazil and its Canadian division Bionatus Botanical Laboratories, Inc.
“We are already at work with Bionatus in Brazil and in Canada on the manufacture of the first product, Propovit enriched with ETST hemp oil. We are also working on a reformulation of Bionatus’ product,” stated ETST CEO and Chief Science Officer, Dr. Michel Aube. “The new formulation will see the product enriched with CBD to boost the suspected anti-inflammatory and bronchial-dilatation properties of the main natural ingredient – Guaco (Mikania glomerata) extract (http://www.bionatus.ca/index.php/en-ca/blog).
Guaco is a Brazilian plant widely used to help treat respiratory conditions. The Brazilian Health Regulatory Agency (ANVISA) has encouraged the use of Guaco, as its effectiveness has been proven by traditional use and the product is widely available OTC in Brazil. Guaco’s actions as an anti-inflammatory, an anti-edema agent, and a bronchodilator have been proven through in-vivo studies using extracts of Mikania glomerata.
ETST and Bionatus have planned a new product that will combine the effects of Mikania glomerata and Cannabis sativa oil for specific patients. Details will be forthcoming shortly.
André Konan PhD , Director of the Laboratory Bionatus Pharmacognosique Inc. states: As we move forward in this project, research results on CBD as well as clinical trials on Guaco and Brazilian honey used in Propovit are increasingly being published. This allows us to better focus our research to bring more innovative products to the market.
The Company plans to share further updates on its CBD IP patent formula, research and development, Form 10 approval, and medical device updates as each progresses.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets, and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:
Earth Science Pharmaceutical
Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharma, Inc. (“ESP”), which is committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics
Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs.
To learn more please visit: www.CannabisThera.com
KannaBidioiD
KannaBidioid, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioiD, Inc. (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.
To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Earth Science Foundation, Inc. (“ESF”), is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech, Inc’s effective CBD products to those in need.
To learn more please visit: www.ETSTFoundtion.org
About Karmavore Superfoods
Born as a passion project by founder Brian Miller, a world renowned yoga teacher, health enthusiast and entrepreneur. Karmavore Superfoods is a superfood based health food company producing premium quality packaged snack foods using only the healthiest, most nutritionally dense ingredients available. Their mission is to make the tastiest and healthiest snacks possible. Their products are formulated by specifically choosing each ingredient based not only on its taste profile, but on its nutritional profile and how it interacts with our system. All of the products are organic, vegan, gluten free, low in sugar and refined sugar free. Not only do the products taste amazing, they leave you feeling great as well.
To learn more please visit: www.karmavoresuperfoods.com
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact: Dave Demarest 305.546.7640 Office Company Contact: www.EarthScienceTech.com Nickolas S. Tabraue President, Director, & Chariman 305.615.2118
Source: Earth Science Tech, Inc.
Sign Up for FREE
Stock Alerts from
to be the first to know when this emerging company issues Breaking News!
What is ETST?
Earth Science Tech (ETST) is a unique Science based Biotechnology company that brings Nature’s Pharmacy to the public.
Earth Science Tech is an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development.
Earth Science Tech, Inc. (ETST) has among the highest quality, purity, and Full Spectrum Industrial Hemp Oil naturally containing CBD (Cannabidiol) on the market. Formulated using superior supercritical CO2 cold liquid extraction, our cannabinoids are kept at the rawest state maintaining all therapeutic properties. Our research, performed alongside the University of Central Oklahoma, DV Biologics laboratory, and other organizations, as well as being suggested in The Institute for Natural Healing’s (INH) Delta 8 Article has demonstrate that we are the top nutritional and dietary supplement brand in the Industrial Hemp space.
ETST’s High Grade Full Spectrum Cannabinoids are derived from Industrial Hemp plants with a high cannabinoid content. The Hemp used is extracted using Super-critical (cold) CO2 fluid extraction to ensure highest quality of cannabinoids and having all the naturally occurring therapeutic properties intact.
ETST’s High Grade Hemp Cannabinoids is a full spectrum extract, not synthetic nor an isolate. It contains a variety of valuable phyto-nutrients, synergistic cannabinoids, essential oils and other compounds found in the original plant.
What are ETST Products
ETST products include CBD (Cannabidiol), a natural constituent of Hemp Oil. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD and presents a continuing stream of overwhelming evidence of significant Health and Wellness benefits including; a digestive aid that regulates appetite and eases symptoms of nausea and vomiting, analgesic pain relief, relief from anxiety, anti-tumour and anti-cancer benefits, and antipsychotic. CBD (cannabidiol) promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 “Cannabinoids as antioxidants and neuroprotectants.”
ETST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products. They come in various formulations and delivery systems such as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs.
Source: https://earthsciencetech.com/